Abraham William T
Division of Cardiovascular Medicine, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio, USA.
Rev Cardiovasc Med. 2006;7 Suppl 1:S33-41.
Intrathoracic impedance monitoring (approved by the US Food and Drug Administration) and implantable hemodynamic monitoring (IHM), which is under investigation, are promising techniques for the improved management of heart failure by detecting early changes in fluid status or hemodynamic congestion. Routine outpatient surveillance of intrathoracic impedance data from implanted devices may significantly reduce the currently high rates of hospital admission/readmission for patients with heart failure. IHM systems may extend such monitoring capabilities. Both emerging approaches for monitoring patients with heart failure may alert clinicians (and possibly patients) to impending decompensation before symptoms appear.
胸内阻抗监测(已获美国食品药品监督管理局批准)以及正在研究中的植入式血流动力学监测(IHM),是通过检测液体状态或血流动力学充血的早期变化来改善心力衰竭管理的有前景的技术。对植入设备的胸内阻抗数据进行常规门诊监测,可能会显著降低目前心力衰竭患者的高住院率/再住院率。IHM系统可能会扩展这种监测能力。这两种用于监测心力衰竭患者的新方法,都可能在症状出现前提醒临床医生(可能还有患者)即将发生失代偿。